This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (9)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Immunization  • Infectious Diseases  • Viral Infections  • Articles for Residents  • Ophthalmology, Other  • Drug Therapy  • Adverse Effects  • Public Health  • Alert me on articles by topic

Richard D. Semba, MD, MPH

Arch Ophthalmol. 2003;121:715-719.

Although smallpox was eradicated worldwide, concerns have been raised about the use of smallpox as a biological weapon. Plans are being considered for smallpox immunization in the United States. Variola virus, the cause of smallpox, and vaccinia virus, used in smallpox immunization, are both orthopoxviruses that are associated with serious ocular complications, including eyelid and conjunctival infection, corneal ulceration, disciform keratitis, iritis, optic neuritis, and blindness. About 5% to 9% of patients with smallpox develop ocular complications, and case-fatality rates reach 20% to 35% among unvaccinated individuals. About 10 to 20 patients develop ocular complications per 1 million smallpox immunizations, usually through autoinoculation, in which the patient transfers vaccinia from the immunization site to the eye. The risk of ocular vaccinia infection may be reduced by instructing patients and individuals in close contact with the vaccinee to wash their hands often and avoid touching the immunization site and their eyes. Topical antiviral therapy, topical steroids, and topical and oral antibiotics have been used to reduce the ocular complications of smallpox immunization. In contrast, there has been little experience with the use of these therapies for the ocular complications of smallpox.

From the Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Md. The author has no relevant financial interest in this article.

RELATED ARTICLE

National Preparedness for Biological Warfare and Bioterrorism: Smallpox and the Ophthalmologist
Dennis G. Maki
Arch Ophthalmol. 2003;121(5):710-711.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

LC16m8, a Highly Attenuated Vaccinia Virus Vaccine Lacking Expression of the Membrane Protein B5R, Protects Monkeys from Monkeypox.
Saijo et al.
J. Virol. 2006;80:5179-5188.
ABSTRACT | FULL TEXT  

The Ocular Complications of Smallpox and Smallpox Immunization
Smith et al.
Arch Ophthalmol 2004;122:1407-1407.
FULL TEXT  

The Ocular Complications of Smallpox and Smallpox Immunization--Reply
Semba
Arch Ophthalmol 2004;122:1407-1408.
FULL TEXT  

National Preparedness for Biological Warfare and Bioterrorism: Smallpox and the Ophthalmologist
Maki
Arch Ophthalmol 2003;121:710-711.
FULL TEXT